open access

Vol 6, No 2 (2021)
Original article
Published online: 2021-06-30
Get Citation

Ki-67 proliferative index correlation to the immunohistochemistry profile in early female breast cancer: a review of 515 cases

Abdalla Saad Abdalla Al-Zawi1, Mohamed Elamass1, Agnieszka Kapturek2, Philip Idaewor1
DOI: 10.5603/MRJ.2021.0026
·
Medical Research Journal 2021;6(2):108-113.
Affiliations
  1. Basildon & Thurrock University Hospital, Nethermayne, Basildon, Essex, United Kingdom
  2. Pratia Medical Research Centre, ul. Poznańska 14, 60-185 Skórzewo k. Poznania, Poland

open access

Vol 6, No 2 (2021)
ORIGINAL ARTICLES
Published online: 2021-06-30

Abstract

Introduction: Many biological markers are used as prognostic and predictive indicators in invasive breast
cancers management. Among them, tumour size, grade, patho-morphological subtype, hormone receptors
status and HER2 receptor expression in addition to Ki-67 proliferative index. Also, they play a key role in
adjuvant treatment decision making. Our aim was to evaluate the association between Ki-67 proliferative
index and breast cancer immunological subtype.

Material and methods:
A total of 515 early invasive patients were enrolled, tumour biological characteristics
as histopathological subtype, immune-histo-chemistry (ER,PR,HER2) status and Ki-67 proliferation index
values have been collected. The Ki-67 index level of 20%, was used as the cut-off point to differentiate
between low and high Ki-67 expression levels. Statistical analysis has been performed using the Chi
square test online tool.

Results:
In this cohort, about 42%, 33%, 7%, and 18% of the cases were grouped as luminal A-like, luminal
B-like, HER2 enriched subtype, and triple-negative, respectively. All luminal A-like patients had Ki-67 level
less than 20%. About 3% of the cohort, are luminal B-like tumours with Ki-67 level less than 20%, where
30.3% of the patients were luminal B-like tumours with Ki-67 level ≥ 20%. In HER2 enriched subtype, Ki-
67 of < 20% level seen in 1.9% of cases, and Ki-67 levels ≥ 20% was observed in 5.2% of the cases. In
the triple-negative group, Ki-67 was 20% or higher in 16% of cases, and only 1.7% of patients had Ki-67
level less than 20%.

Conclusion:
Luminal A-like tumours were the most frequently encountered subtype, they have low Ki-67
levels and are known to be of a low histological grade tumour, and usually associated with a good prognosis.
Also, data indicates that high Ki-67 levels are seen more often in Luminal B-Like breast cancers as
well as in triple-negative breast cancers and HER2 enriched tumours.

Abstract

Introduction: Many biological markers are used as prognostic and predictive indicators in invasive breast
cancers management. Among them, tumour size, grade, patho-morphological subtype, hormone receptors
status and HER2 receptor expression in addition to Ki-67 proliferative index. Also, they play a key role in
adjuvant treatment decision making. Our aim was to evaluate the association between Ki-67 proliferative
index and breast cancer immunological subtype.

Material and methods:
A total of 515 early invasive patients were enrolled, tumour biological characteristics
as histopathological subtype, immune-histo-chemistry (ER,PR,HER2) status and Ki-67 proliferation index
values have been collected. The Ki-67 index level of 20%, was used as the cut-off point to differentiate
between low and high Ki-67 expression levels. Statistical analysis has been performed using the Chi
square test online tool.

Results:
In this cohort, about 42%, 33%, 7%, and 18% of the cases were grouped as luminal A-like, luminal
B-like, HER2 enriched subtype, and triple-negative, respectively. All luminal A-like patients had Ki-67 level
less than 20%. About 3% of the cohort, are luminal B-like tumours with Ki-67 level less than 20%, where
30.3% of the patients were luminal B-like tumours with Ki-67 level ≥ 20%. In HER2 enriched subtype, Ki-
67 of < 20% level seen in 1.9% of cases, and Ki-67 levels ≥ 20% was observed in 5.2% of the cases. In
the triple-negative group, Ki-67 was 20% or higher in 16% of cases, and only 1.7% of patients had Ki-67
level less than 20%.

Conclusion:
Luminal A-like tumours were the most frequently encountered subtype, they have low Ki-67
levels and are known to be of a low histological grade tumour, and usually associated with a good prognosis.
Also, data indicates that high Ki-67 levels are seen more often in Luminal B-Like breast cancers as
well as in triple-negative breast cancers and HER2 enriched tumours.

Get Citation

Keywords

breast neoplasms, Ki-67 proliferation index, eestrogen receptor, Progesterone receptor, HER2

About this article
Title

Ki-67 proliferative index correlation to the immunohistochemistry profile in early female breast cancer: a review of 515 cases

Journal

Medical Research Journal

Issue

Vol 6, No 2 (2021)

Article type

Original article

Pages

108-113

Published online

2021-06-30

DOI

10.5603/MRJ.2021.0026

Bibliographic record

Medical Research Journal 2021;6(2):108-113.

Keywords

breast neoplasms
Ki-67 proliferation index
eestrogen receptor
Progesterone receptor
HER2

Authors

Abdalla Saad Abdalla Al-Zawi
Mohamed Elamass
Agnieszka Kapturek
Philip Idaewor

References (25)
  1. Kanyılmaz G, Yavuz BB, Aktan M, et al. Prognostic importance of Ki-67 in breast cancer and its relationship with other prognostic factors. Eur J Breast Health. 2019; 15(4): 256–261.
  2. Al-Zawi A. Ki -67 proliferative index as a predictive tool for axillary pathological complete response in node-positive breast cancer. International Journal of Medical Science. 2020; 7(11): 1–4.
  3. Fulton R. Getting a Grip on Ki-67. Appl Immunohistochem Mol Morphol. 2021; 29(2): 83–85.
  4. Caputo A, D'Antonio A, Memoli D, et al. Ki67 in gleason pattern 3 as a marker of the presence of higher-grade prostate cancer. Appl Immunohistochem Mol Morphol. 2021; 29(2): 112–117.
  5. Colón-Caraballo M, García M, Mendoza A, et al. Human endometriosis tissue microarray reveals site-specific expression of estrogen receptors, progesterone receptor, and Ki67. Appl Immunohistochem Mol Morphol. 2019; 27(7): 491–500.
  6. Hu HY, Liu Hu, Zhang JW, et al. Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepatogastroenterology. 2012; 59(120): 2640–2643.
  7. Nielsen PS, Riber-Hansen R, Raundahl J, et al. Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. Arch Pathol Lab Med. 2012; 136(6): 627–634.
  8. Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016; 69(3): 209–214.
  9. Yagi T, Inoue N, Yanai A, et al. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 2016; 23(2): 224–230.
  10. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66(6): 512–516.
  11. Saad Abdalla Al-Zawi A, Syed A. Ki67 Proliferation index as a prognostic and predictive tool for pathological response after upfront chemotherapy in breast cancer. . Paripex indian Journal of Research . 2020; 9(11).
  12. Mukai H, Yamaguchi T, Takahashi M, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. Br J Cancer. 2020; 122(12): 1747–1753.
  13. Zheng JN, Sun YF, Pei DS, et al. Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. Life Sci. 2005; 76(16): 1873–1881.
  14. Mukai H, Yamaguchi T, Takahashi M, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. Br J Cancer. 2020; 122(12): 1747–1753.
  15. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109(1): 123–139.
  16. Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009; 16(10): 2705–2710.
  17. Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016; 157(2): 363–371.
  18. Badowska-Kozakiewicz AM, Budzik MP. Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol (Pozn). 2016; 20(6): 436–443.
  19. Toft DJ, Cryns VL. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2011; 25(2): 199–211.
  20. Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2010; 17(2): 118–124.
  21. Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol. 2011; 3(2).
  22. Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020; 84: 101965.
  23. Hashmi AA, Hashmi KA, Irfan M, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019; 12(1): 605.
  24. Pérez-López ME, García-Gómez J, Alves MT, et al. Ki-67 is a prognostic marker for hormone receptor positive tumors. Clin Transl Oncol. 2016; 18(10): 996–1002.
  25. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016; 13(4): 496–504.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.